October 21, 2019
This feature highlights changes in clinical research organizations’ personnel.
Alexion Pharmaceuticals has named Tanisha Carino chief corporate affairs officer. Carino was most recently executive director at FasterCures.
Aligos Therapeutics has named Matthew McClure executive vice president and chief medical officer. McClure was previously CMO at Second Genome.
Kevin Norrett was named senior vice president and chief commercial officer, Tracy Mayne was named vice president of medical affairs, Daniel Lazzetti was named vice president of human resources and David Upchurch was named vice president of technical operations at Angion Biomedica. Previously, Norrett was vice president of marketing, market access and commercial operations at Aimmune Therapeutics. Mayne was head of health policy and systems research at Genetech. Lazzetti was head of human resources for Five Prime Therapeutics. Upchurch most recently served as head of quality for Napo Pharmaceuticals.
Mira Leiwant has been named vice president of regulatory affairs, quality and clinical affairs at Anika Therapeutics. Previously, Leiwant served as vice president of regulatory affairs at BTG International.
Airidis Pharmaceuticals has appointed Paul Mendelman as interim chief medical officer. Mendelman was most recently vice president of medical at Takeda Vaccines.
Aroa Biosurgery has named Brad Adams as the first vice president of commercial. Adams was most recently vice president of sales at Acell.
Hector Bremner has been appointed chief executive officer and Bob Rai has been named president of Avricore Health. Bremner was previously executive vice president of Avricore’s branding, strategic communications and public affairs. Rai previously held the position of CEO at the company.
James Sapirstein has been appointed chief executive officer at AzurRX BioPharma. Sapirstein was CEO for ContraVir Pharmaceuticals, formally known as Hepion.
Merav Bassan has been named chief development officer at BiomX. Bassan is a former vice president of translational sciences at Teva Pharmaceutical Industries.
Kevin Buchi was named chief executive officer at BioSpecifics Technologies. Buchi recently served as president and CEO of TetraLogic Pharmaceuticals.
Checkmate Pharmaceuticals has named James Woolridge chief medical officer and Steven Hamburger vice president of regulatory affairs. Woolridge was previously affiliated with Aeglea BioTherapeutics where he was CMO; Hamburger was recently vice president of regulatory affairs and quality assurance at Tarveda Therapeutics.
Covance has appointed Paul Kirchgraber chief executive officer. Kirchgraber last served as senior vice president and head of Covance’s clinical trials testing solutions.
CytomX Therapeutics has named Amy Peterson chief development officer. Peterson most recently served as chief medical officer of BeiGene.
Jeb Ledell has been named chief operating officer at Enzyvant Sciences. Ledell was formerly COO at Compass Therapeutics.
Galera Therapeutics has appointed Christopher Degnan chief financial officer. Degnan was most recently with Verrica Pharmaceuticals as CFO.
Gilead Sciences has named Andrew Dickinson chief financial officer. Dickinson served as chief strategy officer at the company prior to his promotion.
Stephen Harrison has been named consultant medical director. Harrison is currently a visiting professor of Hepatology at the Radcliffe department of medicine at the University of Oxford, the medical director for Pinnacle Clinical Research and the president of Summit Clinical Research.
John Ratliff has been named chief executive officer and Judi Seltz chief human resources officer at LabCorp Diagnostics. Ratliff was previously CEO of Covance. Seltz formerly served as vice president of human resources for the global human health division at Merck.
Dana Washburn has been appointed chief medical officer at Lyra Therapeutics. Washburn was corporate vice president and head of global medical services for Parexel International.
Mundipharma Pharmaceuticals has added to its leadership with Matthew Homent named Ireland country manager. Homent previously served as director of commercial operations at Napp Pharmaceuticals Limted in the UK.
Oncology Pharma has named Vijay Mahant chief scientific officer and chief operating officer. Mahant served as founder and chief executive officer of MediLite Diagnostika.
Orchestra BioMed named Juan Lorenzo vice president of product development for focal therapies and Paul Goode vice president of product development for bioelectronic therapies. Lorenzo was recently director of research and development at CERENOVUS, a Johnson & Johnson company. Goode was vice president of research and development and chief technology officer for GERD.
Marella Thorell has been appointed chief financial officer at Palladio Biosciences. Thorell previously served as CFO and chief operating officer and an executive director at Realm Therapeutics.
Pharma-Olam named Robert Davie chief executive officer. Davie was formerly vice president and general manager of global clinical development at Covance.
Kerry Ingalls has been named chief operating officer at Poseida Therapeutics. Ingralls previously oversaw clinical and commercial manufacturing at Amgen.
Ronald Herbst has been appointed chief scientific officer at Pyxis Oncology. Herbst was vice president of research and development and head of oncology research at MedImmune.
Mark Foley was named president and chief executive officer at Revance Therapeutics. Previously, Foley was CEO of Zeltiq Aesthetics.
Seelos Therapeutics has appointed Scott Applebaum as strategic regulatory consultant. Applebaum was most recently president of Context Therapeutics.
Vaccibody AS has named Siri Torhaug chief medical officer. Before joining Vaccibody, Torhaug served as the medical team lead for oncology at AstraZeneca.